ABBOTT PARK, Ill., July 10, 2014 /PRNewswire/ -- Today's announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT) has made in China, deepening its commitment in the country. In June, Abbott opened a state-of-the-art nutritional manufacturing facility in Jiaxing, and earlier this year, Abbott opened two research and development centers in Shanghai. In 2014, Abbott has announced more than US$400 million (2.5 billion RMB) of investments in its China operations.
Abbott has made these investments in order to improve people's nutrition and health, and further establish the company as a long-term partner in China's development. Today, Abbott has more than 4,000 employees in China. Abbott investments and engagements in China include:
"Our goal is to help people live healthier lives," said Miles D. White, chairman and chief executive officer, Abbott. "That means investing in the countries where we live and work. We're committed to using our science, our product quality and educational efforts to raise the level of health in China and around the world."
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.
In China, Abbott has more than 4,000 employees working in manufacturing, research and development, logistics, sales and marketing. Primary locations in China are in Shanghai, Beijing and Jiaxing.